Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 – results from 1 January to 30 September, 2014
DGAP-News: Veloxis Pharmaceuticals A/S 07.11.2014 / 08:48 --------------------------------------------------------------------- Investor service announcement no. 7/2014 To: NASDAQ OMX Copenhagen Hørsholm, Denmark, 7 November, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 - results from 1 January to 30 September, 2014 Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for the third Quarter 2014 on Wednesday 12 November, 2014 after 05:00 PM CET. Veloxis' Management will host an accompanying conference call to discuss the financial results on Thursday 13 November, 2014 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EST (New York), To access the live conference call, please dial one of the following numbers: +45 32 72 80 18 (Denmark) +44 (0) 1452 555 131 (UK) +1 866 682 8490 (USA) Access code 28069222 Following the conference call, a recording will be available on the company's website http://www.veloxis.com. For more information, please contact: John D. Weinberg Johnny Stilou EVP, Chief Operating Officer EVP, Chief Financial Officer Mobile: +1 908 304 3389 Mobile: +45 21 227 227 Email: jdw@veloxis.com Email: jst@veloxis.com About Veloxis Pharmaceuticals Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose(R), is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com. News Source: NASDAQ OMX --------------------------------------------------------------------- 07.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Veloxis Pharmaceuticals A/S Denmark ISIN: DK0060048148 End of News DGAP News-Service --------------------------------------------------------------------- 295740 07.11.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden